Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals

Pharming reported positive results from its Phase II trial of leniolisib, where 10 of 11 evaluable participants experienced reduced spleen volume and all 4 participants showed decreased lymph node size. The drug was well-tolerated and demonstrated improvements in various measures of immune dysregulation, prompting all participants to opt for continued treatment in a long-term extension study. This data supports the potential of targeted PI3Kδ inhibition in treating genetic primary immunodeficiencies.